Ipca Laboratories Ltd (nse:IPCALAB) Share Price

Company Profile

Business description
Ipca Laboratories Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company is an integrated pharmaceutical company manufacturing and marketing over 350 formulations and various API's covering various therapeutic segments. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), and Losartan. The company has only one reportable primary business segment, pharmaceuticals. Geographically, the maximum revenue is derived from outside India, mainly from Europe, Africa, the Americas, Asia, etc.
Contact
125, Kandivli Industrial Estate
Kandivli (West)
MumbaiMH400067
IND
T: +91 2262105000
https://www.ipca.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
23,467

Recommended

We see regulatory risk from both the US and Chinese governments.

Seth Goldstein, CFA | 25 October 2026

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,926.60	20.80	0.23%
CAC 40	7,837.10	54.28	0.70%
DAX 40	25,381.56	199.91	0.79%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,729.84	39.48	0.37%
HKSE	23,211.81	118.44	0.51%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,189.65	503.51	-0.80%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,809.90	14.70	0.17%
SSE Composite Index	3,697.52	7.04	0.19%